AH
AVIR icon

Andreas Halvorsen’s Atea Pharmaceuticals AVIR Stock Holding History

Andreas Halvorsen’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,655,087
Closed -$58M – 109
2021
Q3 		$58M Buy
+1,655,087
New +$45.9M 0.16% 80

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return

Andreas Halvorsen's AVIR Position: Q4 2021 in Review

Andreas Halvorsen sold out of Atea Pharmaceuticals (AVIR) in Q4 2021, closing a stake of 1,655,087 shares — an estimated $58M sold.

Andreas Halvorsen first reported a position in AVIR in Q3 2021 and held it in 1 quarter. The position peaked at $58M in Q3 2021. 143 funds tracked by Wall St. Rank hold AVIR as of Q4 2021.

  • Andreas Halvorsen reported no remaining Atea Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Andreas Halvorsen sold 1,655,087 Atea Pharmaceuticals shares in Q4 2021, an estimated $58M.
  • Andreas Halvorsen first reported a position in Atea Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Andreas Halvorsen's Atea Pharmaceuticals position peaked at $58M in Q3 2021.
  • 143 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2021.

Based on Viking Global Investors's 13F filing for Q4 2021, filed 14 Feb 2022.